Kigamicine D

Kigamicin D shows activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) with MICs of 0.025-0.78 μg/mL. Kigamicin D also shows effect against L-1210 LB32T and other genera tumor cells with IC50 of 1 μg/mL[1].

680571-52-2

12352005

Bacterial

Anti-infection

Cancer; Infection

OC1=C2C3=C(OCO[C@]3([H])CC4=CC(C[C@@]5(N(CCO5)C6=O)C)=C6C(O)=C42)C7=C1C(C8=C([C@H]([C@@H](C[C@@H]8O)O[C@@H]9O[C@@H]([C@H](CC9)O[C@H]%10C[C@H]([C@@H]([C@H](O%10)C)O[C@H]%11C[C@H]([C@@H]([C@H](O%11)C)O)OC)OC)C)O)O7)=O

C48H59NO19

953.98

[1]Jie Lu, et al. Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvation. Cancer Sci. 2004 Jun;95 (6) :547-52.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-N14484/

Natural Products

No Development Reported